Recently, the p21-activated kinase 1 (PAK1) has emerged as a potential therapeutic target in cancer, due to its key influence in a variety of oncogenic signaling pathways, including leukemia (Rane and Minden, 2014). This evidence concerns the gene PAK1 and cancer.